Ceapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent February 5, 2020
Ceapro Inc. Secures DTC Eligibility for Publicly Traded Shares Under Ticker OTCQZ: CRPOF January 31, 2020
Ceapro Inc. Announces Publication of Results for a New PGX Processed Chemical Complex in the Journal of Supercritical Fluids December 17, 2019
Ceapro Inc. Reports 2019 Third Quarter Financial Results and Operational Highlights November 13, 2019
Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides October 29, 2019
Ceapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering Research September 25, 2019
